https://doi.org/10.55788/6950d74d
In a trial presented by Dr Anders Pitzner-Fabricius (Rigshospitalet Copenhagen, Denmark), physically inactive adults with persistent asthma were randomised 2:1 to either a regimen of high-intensity interval training 3 times per week for 6 months (n=102) or a control group of usual lifestyle (n=48) [1]. Both arms were followed up without intervention for an additional 6 months.
The results showed that the change in mean inhaled corticosteroid use (in micrograms) was reduced at 6 months in the high-intensity interval training arm by -234 micrograms (95% CI reduction -391 to -77; P=0.004), and even further by 12 months, even without intervention for the second 6-month period (-314 micrograms; 95% CI -477 to -151; P=0.002) (see Figure). When stratified by adherence to the high-intensity interval training regimen, the investigators reported that 71.4% of those with high adherence reduced their inhaled corticosteroid use by at least 25%, as opposed to 48.8% of the control group (P=0.09).
Figure: High-intensity interval exercise resulted in a 24% reduction in daily inhaled corticosteroids versus control after 6 months, without compromising asthma control [1]
Dr Pitzner-Fabricius concluded that high-intensity interval training for adults with asthma has the potential to improve asthma control, reduce inhaled corticosteroid use, and has a potentially long-term positive lifestyle impact.
- Pitzner-Fabricius A, et al. The effects of high-intensity interval training on inhaled corticosteroids dose in patients with asthma ā a randomized controlled trial. Session A16, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« Threeās a crowd for triple therapy in COPD Next Article
NAVIGATOR steers asthma patients to tezepelumab »
« Threeās a crowd for triple therapy in COPD Next Article
NAVIGATOR steers asthma patients to tezepelumab »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
June 16, 2021
Obstructive sleep apnoea associated with lower cognition
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com